Thanx Lang. Yes, it looks good. Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX - News), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, presented results from its positive Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) at Digestive Disease Week (DDW) 2010 in New Orleans, Louisiana.
UP in pre-market…Chart: trend should hold: Gann’s rule of 4. Watching vol.